Cargando…

Plant-derived compounds for treating autosomal dominant polycystic kidney disease

Autosomal dominant polycystic kidney disease (ADPKD), the most common monogenic hereditary kidney disease, is the fourth leading cause of end-stage kidney disease worldwide. In recent years, significant progress has been made in delaying ADPKD progression with different kinds of chemical drugs, such...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Jieting, Chen, Jiaxin, Xu, Jing, Xue, Cheng, Mao, Zhiguo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10479581/
https://www.ncbi.nlm.nih.gov/pubmed/37675342
http://dx.doi.org/10.3389/fneph.2023.1071441
_version_ 1785101622236413952
author Zhang, Jieting
Chen, Jiaxin
Xu, Jing
Xue, Cheng
Mao, Zhiguo
author_facet Zhang, Jieting
Chen, Jiaxin
Xu, Jing
Xue, Cheng
Mao, Zhiguo
author_sort Zhang, Jieting
collection PubMed
description Autosomal dominant polycystic kidney disease (ADPKD), the most common monogenic hereditary kidney disease, is the fourth leading cause of end-stage kidney disease worldwide. In recent years, significant progress has been made in delaying ADPKD progression with different kinds of chemical drugs, such as tolvaptan, rapamycin, and somatostatin. Meanwhile, numerous plant-derived compounds have been investigated for their beneficial effects on slowing ADPKD progression. Among them, saikosaponin-d, Ganoderma triterpenes, curcumin, ginkgolide B, steviol, resveratrol, Sparganum stoloniferum Buch.-Ham, Cordyceps sinensis, triptolide, quercitrin, naringin, cardamonin, gambogic acid, and olive leaf extract have been found to retard renal cyst development by inhibiting cell proliferation or promoting cell apoptosis in renal cyst-lining epithelial cells. Metformin, a synthesized compound derived from French lilac or goat’s rue (Galega officinalis), has been proven to retard the progression of ADPKD. This review focuses on the roles and mechanisms of plant-derived compounds in treating ADPKD, which may constitute promising new therapeutics in the future.
format Online
Article
Text
id pubmed-10479581
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-104795812023-09-06 Plant-derived compounds for treating autosomal dominant polycystic kidney disease Zhang, Jieting Chen, Jiaxin Xu, Jing Xue, Cheng Mao, Zhiguo Front Nephrol Nephrology Autosomal dominant polycystic kidney disease (ADPKD), the most common monogenic hereditary kidney disease, is the fourth leading cause of end-stage kidney disease worldwide. In recent years, significant progress has been made in delaying ADPKD progression with different kinds of chemical drugs, such as tolvaptan, rapamycin, and somatostatin. Meanwhile, numerous plant-derived compounds have been investigated for their beneficial effects on slowing ADPKD progression. Among them, saikosaponin-d, Ganoderma triterpenes, curcumin, ginkgolide B, steviol, resveratrol, Sparganum stoloniferum Buch.-Ham, Cordyceps sinensis, triptolide, quercitrin, naringin, cardamonin, gambogic acid, and olive leaf extract have been found to retard renal cyst development by inhibiting cell proliferation or promoting cell apoptosis in renal cyst-lining epithelial cells. Metformin, a synthesized compound derived from French lilac or goat’s rue (Galega officinalis), has been proven to retard the progression of ADPKD. This review focuses on the roles and mechanisms of plant-derived compounds in treating ADPKD, which may constitute promising new therapeutics in the future. Frontiers Media S.A. 2023-02-03 /pmc/articles/PMC10479581/ /pubmed/37675342 http://dx.doi.org/10.3389/fneph.2023.1071441 Text en Copyright © 2023 Zhang, Chen, Xu, Xue and Mao https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Nephrology
Zhang, Jieting
Chen, Jiaxin
Xu, Jing
Xue, Cheng
Mao, Zhiguo
Plant-derived compounds for treating autosomal dominant polycystic kidney disease
title Plant-derived compounds for treating autosomal dominant polycystic kidney disease
title_full Plant-derived compounds for treating autosomal dominant polycystic kidney disease
title_fullStr Plant-derived compounds for treating autosomal dominant polycystic kidney disease
title_full_unstemmed Plant-derived compounds for treating autosomal dominant polycystic kidney disease
title_short Plant-derived compounds for treating autosomal dominant polycystic kidney disease
title_sort plant-derived compounds for treating autosomal dominant polycystic kidney disease
topic Nephrology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10479581/
https://www.ncbi.nlm.nih.gov/pubmed/37675342
http://dx.doi.org/10.3389/fneph.2023.1071441
work_keys_str_mv AT zhangjieting plantderivedcompoundsfortreatingautosomaldominantpolycystickidneydisease
AT chenjiaxin plantderivedcompoundsfortreatingautosomaldominantpolycystickidneydisease
AT xujing plantderivedcompoundsfortreatingautosomaldominantpolycystickidneydisease
AT xuecheng plantderivedcompoundsfortreatingautosomaldominantpolycystickidneydisease
AT maozhiguo plantderivedcompoundsfortreatingautosomaldominantpolycystickidneydisease